Entity
  • Rarecells

    Created in 2010
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    1,631 1,631
  • Activities

  • Technologies

  • Entity types

  • Location

    75006 Paris, France

    Paris

    France

  • Employees

    Scale: 11-50

    Estimated: 24

  • Engaged corporates

    1
    1 0
  • Added in Motherbase

    1 year, 6 months ago
Description
  • Value proposition

    Detect and defeat cancer from its start through a simple blood draw.

    Rarecells develops and commercializes the ISET technology to isolate Circulating Cancer Cells for early cancer diagnosis and medical research.


    Rarecells® Diagnostics was created in 2010 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to make the scientific and technological advances developed by her team available to research teams and patients. Rarecells® Diagnostics’ core product is the patented ISET® (Isolation by SizE of Tumor cells) Technology.

    Rarecells® Diagnostics has the exclusive license of patents belonging to the French Public Institutions University Paris Descartes, Assistance Publique Hôpitaux de Paris and INSERM protecting the Rarecells® Device and its consumables, as well as the analyses performed on cells isolated using the Rarecells® System.

    Rarecells® Diagnostics is a science-driven company. We are scientists working for scientists and patients. We care about bringing benefits to the patients.The team delivers customer satisfaction by manufacturing high quality products and providing high-level scientific assistance.

    Rarecells® and ISET® are registered trademarks of Rarecells SAS.

    In Vitro Medical Device and Liquid Biopsy

  • Original language

    Detect and defeat cancer from its start through a simple blood draw.

    Rarecells develops and commercializes the ISET technology to isolate Circulating Cancer Cells for early cancer diagnosis and medical research.


    Rarecells® Diagnostics was created in 2010 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to make the scientific and technological advances developed by her team available to research teams and patients. Rarecells® Diagnostics’ core product is the patented ISET® (Isolation by SizE of Tumor cells) Technology.

    Rarecells® Diagnostics has the exclusive license of patents belonging to the French Public Institutions University Paris Descartes, Assistance Publique Hôpitaux de Paris and INSERM protecting the Rarecells® Device and its consumables, as well as the analyses performed on cells isolated using the Rarecells® System.

    Rarecells® Diagnostics is a science-driven company. We are scientists working for scientists and patients. We care about bringing benefits to the patients.The team delivers customer satisfaction by manufacturing high quality products and providing high-level scientific assistance.

    Rarecells® and ISET® are registered trademarks of Rarecells SAS.

Corporate interactions BETA
Corporate TypeTweets Articles
France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

19 Apr 2024


Similar entities
Loading...
Loading...
Social network dynamics